Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: small molecule (oral menin inhibitor)
Target Menin
Partnerships Licensed from Vitae Pharmaceuticals (AbbVie subsidiary): exclusive worldwide license to menin-KMT2A interaction inhibitors
Indications
Relapsed/refractory acute leukemia with KMT2A translocation (adults and pediatrics 1+)(Approved)
Relapsed/refractory acute myeloid leukemia with susceptible NPM1 mutation (adults and pediatrics 1+, no satisfactory alternative)(Approved)
Myelofibrosis (MF)(Phase 1)
Catalysts
— Q4 2026
— Q4 2026
— 2H 2026
— end 2026
Status note FDA approvals: Nov 2024 for R/R KMT2A-translocated acute leukemia; Oct 2025 for R/R NPM1m AML. Phase 3 EVOLVE-2 (newly diagnosed NPM1m/KMT2Ar AML, unfit for intensive chemo) and REVEAL-ND (newly diagnosed NPM1m AML with intensive chemo) ongoing. Proof-of-principle Phase 1/2 of revumenib in MF to initiate Q4 2026 (initial data expected 2H 2027).
Partnerships Incyte: worldwide development/commercialization collaboration; US co-commercialization 50/50, Incyte commercializes ex-US (55%/45% development cost split). Royalty Pharma purchased US revenue-stream rights ($350M upfront, Nov 2024). Licensed from UCB Biopharma (exclusive worldwide license)
Indications
Chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (adults and pediatrics >=40 kg)(Approved)
Newly diagnosed cGVHD (with ruxolitinib or corticosteroids)(Phase 3)
Idiopathic pulmonary fibrosis (IPF)(Phase 2)
Catalysts
— Q4 2026
— Q4 2026
— early 2028
Status note FDA approved Aug 2024 for cGVHD post >=2 lines. Phase 2 trial with ruxolitinib in newly diagnosed cGVHD (topline Q4 2026); pivotal Phase 3 with corticosteroids in newly diagnosed cGVHD (topline early 2028). Phase 2 MAXPIRe in IPF (topline Q4 2026).
SNDX-4321
Preclinical · ActiveModality: small molecule (mutant-selective allosteric EGFR inhibitor, CNS-penetrant)
Target EGFR (mutant-selective, allosteric; L858R and other mutations)
Partnerships Exclusive worldwide license (announced July 2026)
Indications
Non-small cell lung cancer (NSCLC)(Preclinical)
Catalysts
— end 2026
— 2027
Status note Announced July 2026. IND submission expected by end 2026; Phase 1 in EGFRm NSCLC to initiate 2027.
SNDX-62122
Preclinical · ActiveModality: small molecule (next-generation menin inhibitor)
Target Menin
Partnerships Internally developed, wholly owned
Indications
Myelofibrosis (MF)(Preclinical)
Catalysts
— 2027
— 2H 2027
Status note Announced July 2026. IND submission and Phase 1 initiation in MF expected 2027; development informed by revumenib proof-of-principle trial in MF.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.